Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference
TEL AVIV, Israel, May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C. Wainwright Global Investment Conference, which will take place May 23-26, 2022.
HC Wainwright Global Investment Conference
Date: Webcast available on demand starting at 7:00am ET May 24 – May 26, 2022
Format: Corporate overview webcast
Webcast Link: https://journey.ct.events/view/47c6f14e-2e3e-4baf-9592-cf2d6c3317f5
Replay: Available at Chemomab website at investors.chemomab.com/events
Chemomab is also participating in one-on-one meetings with investors. For more information, visit hcwevents.com/globalconference/.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in late 2022.
Contacts: | |
Investor Relations: | Media: |
Irina Koffler | Barbara Lindheim |
LifeSci Advisors, LLC | Chemomab Therapeutics |
Phone: +1 917-734-7387 | Consulting Vice President |
Investor & Public Relations, | |
Strategic Communications | |
Phone: +1 917-355-9234 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-hc-wainwright-global-investment-conference-301549851.html
SOURCE Chemomab Therapeutics, Ltd.
